Evidence map›Paper›PMID 40836052›Full record

ArticleScientific reports2025

Temporal trends of a cellular host response test for sepsis and a comparison with selected biomarkers of inflammation and infection.

Matthew S Berlinger, Matt Sorrells, Christopher B Thomas, Tonya Jagneaux, James E Walker, Jennifer Daigle, Heather Quiriarte, Youyoung Kim, Guillaume Spielmann, Debbie Robertson and 16 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Matthew S BerlingerOur Lady of the Lake Regional Medical Center, 5246 Brittany Drive, Baton Rouge, LA, 70808, USA.
Matt SorrellsCytovale, Inc, San Francisco, CA, USA.
Christopher B ThomasFranciscan Missionaries of Our Lady Health System, Baton Rouge, LA, USA.
Tonya JagneauxOur Lady of the Lake Regional Medical Center, 5246 Brittany Drive, Baton Rouge, LA, 70808, USA.
James E WalkerOur Lady of the Lake Regional Medical Center, 5246 Brittany Drive, Baton Rouge, LA, 70808, USA.
Jennifer DaigleLouisiana State University Health Sciences Center, New Orleans, LA, USA.
Heather QuiriarteLouisiana State University, Baton Rouge, LA, USA.
Youyoung KimLouisiana State University, Baton Rouge, LA, USA.
Guillaume SpielmannLouisiana State University, Baton Rouge, LA, USA.
Debbie RobertsonJohns Hopkins University, Baltimore, MD, USA.
Susan Park OchsnerJohns Hopkins University, Baltimore, MD, USA.
Gideon AvornuJohns Hopkins University, Baltimore, MD, USA.
Katherine FenstermacherJohns Hopkins University, Baltimore, MD, USA.
Elijah James KurienJohns Hopkins University, Baltimore, MD, USA.
Camille KingJohns Hopkins University, Baltimore, MD, USA.
Adenine Cembellin-KaoJohns Hopkins University, Baltimore, MD, USA.
Chase YonamineJohns Hopkins University, Baltimore, MD, USA.
Querino MaiaJohns Hopkins University, Baltimore, MD, USA.
Maciej ObrebskiJohns Hopkins University, Baltimore, MD, USA.
David N HagerJohns Hopkins University, Baltimore, MD, USA.
Roya SheybaniCytovale, Inc, San Francisco, CA, USA.
Henry T K TseCytovale, Inc, San Francisco, CA, USA.
Ajay M ShahCytovale, Inc, San Francisco, CA, USA.
Robert ScogginsKootenai Health, Coeur d'Alene, ID, USA.
Hollis R O'NealOur Lady of the Lake Regional Medical Center, 5246 Brittany Drive, Baton Rouge, LA, 70808, USA. honeal@lsuhsc.edu.
Richard RothmanDepartment of Emergency Medicine, Johns Hopkins University, Baltimore, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis, a condition characterized by immune dysregulation, is the leading cause of in-hospital mortality and requires rapid treatment. Assessing immune dysregulation has been challenging. The IntelliSep Index (ISI), a novel biomarker which leverages microfluidic deformability cytometry to assess immune activation, has been evaluated as a test for Emergency Department use but it is unclear how the signal evolves as patient condition evolves. In a 47-patient cohort with hospital stays ≤ 14 days, ISI provided a good indicator of disease progression by blinded physician review. ISI trends correlated with clinical improvement over time. During the first 12 h following presentation, ISI was unaffected by antibiotic treatment initiated in the emergency department (ED). After this period however, ISI values declined, reflecting the patient's response to treatment, with Band 3 patients showing a 20% decline within the first two days of admission. ISI trends preceded Sequential Organ Failure Assessment (SOFA) score changes by two days. ISI also provided more stable and timely disease state assessments compared to traditional biomarkers (PCT, CRP, IL-6, and neutrophil elastase). Larger studies are needed to validate these findings and assess ISI's clinical utility as a prognosticator of sepsis progression and treatment response.

Indexed as

BiomarkersInflammationSepsisAgedDisease ProgressionEmergency Service, HospitalFemaleHumansInterleukin-6MaleMiddle AgedOrgan Dysfunction ScoresBiomarkersInterleukin-6Antimicrobial stewardshipImmune activationIntelliSep Index (ISI)Organ dysfunctionSepsis biomarkersSepsis diagnosis

Identifiers

PMID40836052
PMCPMC12368155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.